Therapeutic approaches to metastasis confined to the liver

Current Oncology Reports

Volumn 3, Issue 2, 2001, Pages 109-115

  Venook, Alan P ^a   Warren, Robert S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clin Oncol; Colorectal Liver Metastasis; Hepatic Metastasis; Liver Metastasis; Liver Resection

Indexed keywords

ANTINEOPLASTIC ANTIMETABOLITE; FLOXURIDINE; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; CHEMOEMBOLIZATION; COLORECTAL TUMOR; HEPATIC ARTERY; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; PATHOLOGY; REVIEW;

ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOEMBOLIZATION, THERAPEUTIC; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; FLOXURIDINE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS;

EID: 0035293848     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-001-0009-4     Document Type: Article

References (52)

1. Kemeny N, Huang Y, Cohen AM, et al.: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999, 341:2039–2048. This study is significant for the apparent benefit of regional HIA therapy following liver metastasis resection in colorectal cancer. It is also important to note the excellent curative rate even for patients in the non-HIA chemotherapy arm. DOI: 10.1056/NEJM199912303412702
2. Schneebaum S, Walker MJ, Young D, et al.: The regional treatment of liver metastases from breast cancer. J Surg Oncol 1994, 55:26–32. DOI: 10.1002/jso.2930550108
3. Rivera E, Fraschini G, Esparza-Guerra L, et al.: Frontline arterial infusion chemotherapy for hepatic metastases in breast cancer patients. Cancer Ther 1999, 2:44–49.
4. Drougas JG, Anthony LB, Blair TK, et al.: Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumor. Am J Surg 1998, 175:408–412. DOI: 10.1016/S0002-9610(98)00042-7
5. Ajani JA, Carrasco H, Charnsangavej C, et al.: Islet cell tumors metastatic to the liver: effective palliation by sequential hepatic artery embolization. Ann Intern Med 1988, 108:340–344.
6. Mavligit GM, Zukiwski AA, Salem PA, et al.: Regression of hepatic metastases from gastrointestinal leiomyosarcoma after hepatic arterial chemoembolization. Cancer 1991, 68:321–323. DOI: 10.1002/1097-0142(19910715)68:2<321::AID-CNCR2820680219>3.0.CO;2-B
7. Venook AP, Eaton V, Chang J, et al.: Chemoembolization for liver metastases from uveal melanoma. GI Cancer 1996, 1:269–273.
8. Clarke MP, Kane RA, Steele G, et al.: Prospective comparison of preoperative imaging and intraoperative ultrasonagraphy in the detection of liver tumors. Surgery 1989, 106:849–855.
9. Fong Y, Cohen AM, Fortner JG, et al.: Liver resection for colorectal metastases. J Clin Oncol 1997, 15:938–946.
10. Scheele J, Stang R, Altendorf-Hofmann A, Paul M: Resection of colorectal liver metastases. World J Surg 1995, 19:59–71. DOI: 10.1007/BF00316981
11. Glasgow RE, Showstack JA, Katz PP, et al.: The relationship between hospital volume and outcomes of hepatic resection for hepatocellular carcinoma. Arch Surg 1999, 134:30–35. This study provides evidence that patients with complicated cancer problems have better outcomes when managed in centers with extensive experience in the procedures being studied. DOI: 10.1001/archsurg.134.1.30
12. Begg CB, Cramer LD, Hoskins WJ, Brennan MF: Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998, 280:1747–1751. DOI: 10.1001/jama.280.20.1747
13. Luna-Perez P, Rodrigues-Corio DF, Arroyo B, Gonzalez-Macouzet J: The natural history of liver metastases from colorectal cancer. Arch Med Res 1998, 29:319–324.
14. Jarnagin WR, Fong Y, Ky A, et al.: Liver resection for metastatic colorectal cancer: assessing the risk of occult irresectable disease. J Am Coll Surg 1999, 188:33–42. An important study to aid in the preoperative decision of the likelihood of a patient having resectable hepatic metastases. DOI: 10.1016/S1072-7515(98)00272-5
15. Cady B, Jenkins RL, Steele GD, et al.: Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome. Ann Surg 1998, 227:566–571. DOI: 10.1097/00000658-199804000-00019
16. Elias D, Cavalcanti A, Sabourin J-C, et al.: Results of 136 curative hepatectomies with a safety margin of less than 10 mm for colorectal metastases. J Surg Oncol 1998, 69:88–93. DOI: 10.1002/(SICI)1096-9098(199810)69:2<88::AID-JSO8>3.0.CO;2-X
17. Fong Y, Fortner J, Sun RL, et al.: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer. Ann Surg 1999, 230:309–321. DOI: 10.1097/00000658-199909000-00004
18. Adam R, Bismuth H, Castaing D, et al.: Repeat hepatectomy for colorectal liver metastases. Ann Surg 1997, 225:51–62. DOI: 10.1097/00000658-199701000-00006
19. Ravikumar T, Steele G: Hepatic cryosurgery. Surg Clin N Am 1989, 69:433–440.
20. Onik G, Kane R, Steele G, et al.: Monitoring hepatic cryosurgery with sonography. AJR Am J Roentgenol 1986, 147:665–669.
21. Curley SA, Izzo F, Delrio P, et al.: Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies. Ann Surg 1999, 230:1–8. A realistic report on the potential role of RFA. DOI: 10.1097/00000658-199907000-00001
22. Jiao LR, Hansen PD, Havlik R, et al.: Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors. Am J Surg 1999, 177:303–306. DOI: 10.1016/S0002-9610(99)00043-4
23. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954, 30:969–985.
24. Collins JM: Pharmacologic rationale for regional drug delivery. J Clin Oncol 1984, 2:498–504.
25. Kemeny N, Daly J, Reichman B, et al.: Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987, 107:459–465.
26. Hohn DC, Stagg RJ, Friedman MA, et al.: A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern Oncology Group Trial. J Clin Oncol 1989, 7:1646–1654.
27. Chang AE, Schneider PD, Sugarbaker PH, et al.: A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 1987, 206:685–693. DOI: 10.1097/00000658-198712000-00001
28. Martin JK, Jr., O’Connell MJ, Wieand HS, et al.: Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 1990, 125:1022–1027.
29. Rougier P, Laplanche AS, Huguier M, et al.: Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial. J Clin Oncol 1992, 10:1112–1118.
30. Allen-Mersh TG, Earlam S, Fordy C, et al.: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 1994, 344:1255–1260. DOI: 10.1016/S0140-6736(94)90750-1
31. Allen-Mersh TG, Earlam S, Fordy C, Abrams K: Continuous hepatic artery floxuridine (FUDR) infusion prolongs overall and normal-quality survival in colorectal liver metastasis (CLM) patients [abstract]. Proc ASCO 1994, 13:202.
32. Meta-analysis Group in Cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 1996, 88:252–258. DOI: 10.1093/jnci/88.5.252
33. Harmantas A, Rotstein LE, Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver. Cancer 1996, 78:1639–1645. DOI: 10.1002/(SICI)1097-0142(19961015)78:8<1639::AID-CNCR1>3.0.CO;2-9
34. Muller H-H: Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2000, 18:243–254.
35. Stagg RJ, Venook AP, Chase JL, et al.: Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991, 83:423–428. DOI: 10.1093/jnci/83.6.423
36. Kemeny N, Seiter K, Niedzwiecki D, et al.: A randomized trial of intrahepatic infusion of fluorodeoxyuridine with dexamethasone versus fluorodeoxyuridine alone in the treatment of metastatic cancer. Cancer 1992, 69:327–334. DOI: 10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U
37. Kemeny N, Seiter K, Conti JA, et al.: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. Cancer 1994, 73:1134–1142. DOI: 10.1002/1097-0142(19940215)73:4<1134::AID-CNCR2820730403>3.0.CO;2-V
38. Kemeny N, Conti JA, Cohen A, et al.: Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994, 12:288–2295.
39. Venook AP: Update on hepatic intra-arterial chemotherapy. Oncology 1997, 11:947–957.
40. Belluco C, Guillem JG, Kemeny N, et al.: p53 nuclear protein overexpression in colorectal cancer: a dominant predictor of survival in patients with advanced hepatic metastases. J Clin Oncol 1996, 14:2696–2701.
41. Cunningham D, Pyrhonen S, James RD, et al.: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352:1413–1418. DOI: 10.1016/S0140-6736(98)02309-5
42. Rothenberg ML, Eckardt JR, Kuhn JG, et al.: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996, 14:1128–1135.
43. Kemeny N, Cohen A, Seiter K, et al.: Randomized trial of hepatic arterial floxuridine, mitomycin, and carmustine versus floxuridine alone in previously treated patients with liver metastases from colorectal cancer. J Clin Oncol 1993, 11:330–335.
44. Levi FA, Zidani R, Vannetzel J-M, et al.: Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994, 86:1608–1617. DOI: 10.1093/jnci/86.21.1608
45. Kemeny MM, Adak S, Lipsitz S, et al.: Results of the Intergroup [Eastern Cooperative Oncology Group (ECOG) and Southwest Oncology Group (SWOG)] prospective randomized study of surgery alone versus continuous hepatic artery infusion of FUDR and continuous systemic infusion of 5FU after hepatic resection for colorectal liver metastases [abstract]. Proc ASCO 1999, 18:264a.
46. Lorenz M, Muller H-H, Schramm H, et al.: Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann Surg 1998, 228:756–762. DOI: 10.1097/00000658-199812000-00006
47. Ron IG, Kemeny NE, Tong B, et al.: Phase I/II study of escalating doses of systemic irinotecan (CPT-11) with hepatic arterial infusion of floxuridine (FUDR) and dexamethasone (D), with or without cryosurgery for patients with unresectable hepatic metastases from colorectal cancer [abstract]. Proc ASCO 1999, 18:236a.
48. Stagg RJ, Venook AP, Chase JL, et al.: Chemoembolization of primary and metastatic liver tumors. Reg Cancer Treat 1992, 2:53–57.
49. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994, 12:1323–1334.
50. Mavligit GM, Zukwiski AA, Ellis LM, et al.: Gastrointestinal leiomyosarcoma metastatic to the liver. Cancer 1995, 75:2083–2088. DOI: 10.1002/1097-0142(19950415)75:8<2083::AID-CNCR2820750809>3.0.CO;2-H
51. Alexander HR, Bartlett DL, Libutti SK, et al.: Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 1998, 16:1479–1489.
52. Anderson SC, Johnson DE, Harris MP, et al.: p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus. Clin Cancer Res 1998, 4:1649–1659.